• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bristol-Myers prices $1.5B senior notes offering

February 23, 2017 By Sarah Faulkner

Bristol-Myers prices $1.5B senior notes offeringBristol-Myers Squibb (NYSE:BMY) said today that it has agreed to sell $1.5 billion of senior unsecured notes in an underwritten public offering.

The offering includes $750 million in  1.6% senior notes due in 2019 and $750 million in 3.3% senior notes due in 2027, according to the New York-based company.

Bristol-Myers said it plans to use the proceeds from the offering to fund its share repurchase program, as well as for general corporate purposes.

Goldman Sachs & Co., Morgan Stanley & Co., Merrill Lynch and others are acting as joint book-running managers.

In December, Bristol-Myers landed an exclusive licensing agreement for PsiOxus Therapeutics‘ ‘armed’ oncolytic virus, NG-348, for the treatment of solid tumors.

According to the agreement, the biopharmaceutical giant will pay PsiOxus $50 million upfront and will assume responsibility for global clinical development and commercialization. PsiOxus will be eligible for $886 million in development, regulatory and sales-based milestones. Bristol-Myers will be responsible for funding the preclinical development of NG-348.

Oncolytic virus therapy makes use of modified viruses that replicate only within tumor cells and stimulate an inflammatory response in the tumor microenvironment. UK-based PsiOxus arms the virus with 2 immuno-therapeutic transgenes using its tumor-specific immuno-gene therapy platform (T-SIGn).

In June 2016, the 2 companies collaborated to study PsiOxus’ ‘unarmed’ oncolytic adenovirus therapeutic, enadenotucirev.

Filed Under: Featured, Funding Roundup Tagged With: Bristol-Myers Squibb Co.

IN CASE YOU MISSED IT

  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS